Other New Drugs
Other New Drugs
- Gilead Sciences, Tibotec to Develop Second Once-Daily HIV Treatment (July 17, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Acyclovir: The Next New HIV Drug? (February 10, 2009)
From Project Inform
- High-Dose Intravenous Immunoglobulin May Reduce Latent HIV Reservoir in Resting CD4+ Cells, Study Suggests (February 10, 2009)
A five-day course of high-dose intravenous immunoglobulin appears to somehow activate replication-competent HIV in the resting CD4+ cells of patients on HAART, ultimately leading to a reduction in those patients' latent HIV reservoirs, according to the results of a nine-patient study presented by Magnus Gisslén, M.D., Ph.D.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Biotechnology Company to Launch Trial of New HIV/AIDS Treatment That Would Target DNA (February 4, 2009)
The treatment involves taking a sample of an HIV-person's CD4 cells and disrupting the CCR5 gene, which is the molecule HIV usually attaches to before infecting the cell. The idea is that, when those modified CD4 cells are put back into an HIVer's body, they'll multiply into an HIV-resistant army of immune cells.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead Aiming to Put Four HIV Drugs in One Pill (January 14, 2009)
From aidsmap.com
- Step Aside, Atripla? New Four-in-One Pill to Enter Development (January 12, 2009)
From Bloomberg.com
- Experimental Treatment Lengthens Lifespan of Monkeys With Simian Version of HIV, Study Says (December 12, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Existing Anti-Obesity Drugs May Be Effective Against Flu, Hepatitis and HIV (September 29, 2008)
From University of Rochester Medical Center
- Major Setback for Experimental Therapeutic HIV Vaccine (July 10, 2008)
In aidsmap.com
- Suppression of Human Protein Reduces HIV's Ability to Enter T Cells, Replicate, Study Finds (April 30, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- New Kind of Antiretroviral, KP-1461, Clinical Trial Recruiting; Interview With Stephen Becker, M.D. (October 11, 2007)
In AIDS Treatment News, from AIDS Treatment News
- Peptide Found in Human Blood Inhibits 60 Strains of HIV, Study Says (April 20, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
|
Advertisement
|
E-Mail
Glossary
Share
